SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

Novartis
Business & Industry News Channel
Novartis
Bristol-Myers Squibb
Novo Nordisk
AstraZeneca
Boehringer Ingelheim
Bayer
Novartis